tipifarnib has been researched along with hydroxyurea in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (hydroxyurea) | Trials (hydroxyurea) | Recent Studies (post-2010) (hydroxyurea) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 8,969 | 741 | 2,156 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexeeva, JA; Bessems, A; Beutel, G; Bordessoule, D; Brandwein, JM; Burnett, AK; De Porre, P; Dombret, H; Golenkov, AK; Harousseau, JL; Howes, AJ; Jedrzejczak, WW; Khuageva, NK; Maertens, J; Martinelli, G; Masszi, T; Mollgard, L; Ossenkoppele, GJ; Park, YC; Robak, T; Thomas, X; Tothova, E; Vidriales, MB | 1 |
1 trial(s) available for tipifarnib and hydroxyurea
| Article | Year |
|---|---|
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Neutropenia; Quinolones; Survival Rate; Time Factors | 2009 |